Lonza enjoys Swiss corporate bid despite recently downgraded borderline rating
Lonza, a Swiss company that makes ingredients for the pharmaceutical, healthcare and life science industries, issued a Sfr350m dual tranche bond on Monday, the latest in a spate of corporate deals in the currency.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts